Advanced Search
MO Wenju, YU Yang. Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Nodepositive[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 534-537. DOI: 10.3971/j.issn.1000-8578.2016.06.020
Citation: MO Wenju, YU Yang. Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Nodepositive[J]. Cancer Research on Prevention and Treatment, 2016, 43(6): 534-537. DOI: 10.3971/j.issn.1000-8578.2016.06.020

Value of 21-gene Assay in Treatment Decisions for Hormone Receptor-positive Nodepositive Nodepositive

  • With the recently increasing number of the women newly diagnosed with early breast cancer(EBC),the 21-gene recurrence score assay has been clinically validated and recommended for the treatment decision making in patients with ER(+), node-negative(N0) EBC. A growing body of evidence from several large phase Ⅲ clinical trials reports similar findings in patients with ER(+), N(+) EBC. This assay could help guide treatment decisions for the patients who are most likely to receive benefit from chemotherapy.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return